BOLD Boundless Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1782303 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY10.1%
TTM EPS YoY7.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-64.6%
ROA-47.8%
ROIC (approx.)-76.5%
Asset turnover—
Leverage & solvency
Liabilities / assets2.9%
Debt / equity0.00x
Current ratio33.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.44M | $13.97M | $9.73M | $9.82M | $10.67M | $12.22M | $12.14M | $13.31M |
| SG&A expense | $4.76M | $10.41M | $4.74M | $4.18M | $4.47M | $4.84M | $5.20M | $4.96M |
| Operating income | -$6.20M | -$24.38M | -$14.47M | -$14.00M | -$15.15M | -$17.06M | -$17.34M | -$18.28M |
| Net income | -$5.36M | -$23.69M | -$13.55M | -$12.88M | -$13.88M | -$15.68M | -$15.76M | -$16.45M |
| EBITDA | -$6.10M | -$23.08M | -$14.19M | -$13.70M | -$14.85M | -$16.76M | -$17.02M | -$17.98M |
| EPS (basic) | -0.23 | -1.06 | -0.60 | — | -0.62 | -0.70 | -0.71 | — |
| EPS (diluted) | -0.23 | -1.06 | -0.60 | — | -0.62 | -0.70 | -0.71 | — |
| Weighted avg. shares (diluted) | 22.86M | 22.45M | 22.41M | — | 22.39M | 22.36M | 22.30M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $34.91M | $20.21M | $17.48M | $17.87M | $14.98M | $14.70M | $15.12M | $27.15M |
| Short-term investments | $27.98M | $52.41M | $75.36M | $89.71M | $102.59M | $112.45M | $123.14M | $125.53M |
| Current assets | $63.59M | $73.65M | $94.62M | $109.61M | $120.16M | $129.69M | $140.36M | $154.39M |
| PP&E, net | $0 | $97,000 | $2.94M | $3.22M | $3.50M | $3.79M | $4.08M | $4.32M |
| Total assets | $63.59M | $73.74M | $140.97M | $157.06M | $168.72M | $179.45M | $191.24M | $206.41M |
| Current liabilities | $1.87M | $7.77M | $9.58M | $12.54M | $11.85M | $9.21M | $6.34M | $8.13M |
| Total liabilities | $1.87M | $7.77M | $54.59M | $58.41M | $58.55M | $56.76M | $54.65M | $55.77M |
| Shareholders' equity | $61.72M | $65.98M | $86.38M | $98.65M | $110.17M | $122.69M | $136.59M | $150.64M |
| Shares outstanding | 23.11M | 22.48M | 22.41M | 22.41M | 22.39M | 22.39M | 22.30M | 22.30M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.88M | -$20.97M | -$14.97M | -$10.11M | -$10.20M | -$11.83M | -$14.53M | -$15.56M |
| Capital expenditure | $0 | $38,000 | $8,000 | $424,000 | $15,000 | $48,000 | $59,000 | $466,000 |
| Free cash flow | -$10.88M | -$21.01M | -$14.98M | -$10.53M | -$10.21M | -$11.88M | -$14.59M | -$16.03M |
| Investing cash flow | $24.77M | $23.07M | $14.59M | $12.97M | $10.48M | $11.29M | $3.06M | $1.82M |
| Financing cash flow | $813,000 | — | — | $24,000 | $0 | — | — | $113,000 |
| Depreciation & amortization | $100,000 | $1.30M | $284,000 | $307,000 | $300,000 | $300,000 | $317,000 | $296,000 |
| Stock-based compensation | $284,000 | $3.22M | $1.37M | $1.33M | $1.30M | $1.69M | $1.80M | $2.01M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.